Clinical trial NCT01147380: Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
Official title: A Novel Immunotherapy for Liver Transplant Patients With Hepatocellular Carcinoma: Anti-tumor Effect of IL2-activated Donor Liver Natural Killer Cell
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Liver Cirrhosis
Hepatocellular Carcinoma
Evidence of Liver Transplantation
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Florida Department of Health
First posted: 2010-06-22
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate feasibility and safety of the adoptive transfer of activated natural killer (NK) cells extracted from cadaveric donor liver graft perfusate for liver transplant recipients with hepatocellular carcinoma (HCC)

Detailed description: To investigate whether adoptive transfer of IL-2 stimulated NKcells extracted from cadaveric donor liver graft exudates into recipient with HCC will lead to prevent recurrence of HCC after liver transplantation.

The method we plan to use is to collect NK cells from the cadaveric donor liver perfusate at the time of organ recovery. The perfusate will be condensed by centrifuging and liver mononuclear cells (LMNC) were isolated by gradient centrifugation. LMNC will be cultured with anti-CD3 antibody. LMNC will be separted into a CD3-/CD56+ NK cell fraction and a non-NK cell fraction. The purity of isolated fractions will be assessed by Flow cytometric analyses. NK cells will be cultured with human recombinant IL-2 in 10% RPMI at 37 ºC in a 5% CO2 incubator. NK cells will be infused intravenously to the recipient with HCC who have liver transplant from the same cadaveric donor at post operative day 4 in attempt to prevent the metastasis and recurrence of HCC.

Eligibility criteria: Inclusion Criteria:

* Primary liver transplant recipient with HCC
* Patients need to meet the liver transplant eligibility criteria
* Cardiac function; cardiac echo will indicate that ejection fraction (EF) \> 35% or right ventricular systolic pressure (RVSP) \< 50mmHg. Stress echo will show no ischemic lesion (if applicable).
* Pulmonary function; SpO2 \>90% or PaO2 \> 60 mmHg, or CT will show no active pulmonary lesion.
* Complete blood count; Platelet \> 20,000 /mm\^3, Hematocrit \> 20%, WBC \> 1,000 /mm\^3
* Eighteen years of age or older
* Ability to provide informed consent
* If female of childbearing potential:

Must not be lactating, must have a negative serum B-human chorionic gonadotropin (HCG) test within 7 days prior to Day of Transplant, and must agree to practice an acceptable and reliable form of contraception during the study Ability to provide informed consent

Exclusion Criteria:

* Living donor liver transplant; a healthy person donates part of his or her liver to the recipient
* Multiple organ transplants
* Prior solid organ or bone marrow transplant recipients
* Fluminant hepatic failure
* The patients regularly receive the hemodialysis more than twice a week before liver transplant
* Status 1 transplants; acute severe disease and defined as a patient with only recent development of liver disease who is in the intensive care unit of the hospital with a life expectancy without a liver transplant of fewer than 7 days
* ABO incompatible transplants
* Transplants utilizing livers from non-heart beating donors; the cardiac death donor
* Recipients of investigational therapy within 90 days prior to transplant procedure
* Acute viral illness
* History of malignancy within 5 years, with exception of: Adequately treated localized squamous or basal cell carcinoma of the skin without evidence or recurrence, and/or Hepatocellular carcinoma
* Illness other than primary liver disease (e.g., severe ischemic heart disease, left ventricular dysfunction, or pulmonary disease), which, in the opinion of the Investigator, may significantly increase the risk of the transplantation procedure
* Current drug or alcohol abuse or, in the opinion of the Investigator, is at risk for poor compliance (no drug testing required)
* Serology positive donor (HCV, HBsAg, HBcAb, HTLV-1, HTLV-3, EBVIgM)
* Poor liver function donor (Total bilirubin \> 3.0 mg/dl, Prothrombin time \> 35 sec),
* Patients who receive intercurrent chemotherapy at the time of enrollment

Primary outcomes:
measure: Side Effect of Cadaveric Donor Liver NK Cell Infusion
timeFrame: 1 year
Secondary outcomes:
measure: NK Cell Infusion-related Toxicity
timeFrame: 1 year
measure: Anti-HCC Effect of This Treatment
timeFrame: 2 year
measure: Anti-HCV Effect of This Treatment (If Applicable)
timeFrame: 2 year
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: Department of Surgery, University of Miami
name: Seigo Nishida, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ohira M, Hotta R, Tanaka Y, Matsuura T, Tekin A, Selvaggi G, Vianna R, Ricordi C, Ruiz P, Nishida S, Tzakis AG, Ohdan H. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma. Cancer Immunol Immunother. 2022 Mar;71(3):589-599. doi: 10.1007/s00262-021-03005-3. Epub 2021 Jul 19.